These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

611 related articles for article (PubMed ID: 27507014)

  • 1. Efficacy and safety of Dexrazoxane (DRZ) in sarcoma patients receiving high cumulative doses of anthracycline therapy - a retrospective study including 32 patients.
    Schuler MK; Gerdes S; West A; Richter S; Busemann C; Hentschel L; Lenz F; Kopp HG; Ehninger G; Reichardt P; Pink D
    BMC Cancer; 2016 Aug; 16():619. PubMed ID: 27507014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anthracycline-induced cardiotoxicity in patients with paediatric bone sarcoma and soft tissue sarcoma.
    Bini I; Asaftei SD; Riggi C; Tirtei E; Manicone R; Biasin E; Basso ME; Agnoletti G; Fagioli F
    Cardiol Young; 2017 Nov; 27(9):1815-1822. PubMed ID: 28780919
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interim Analysis of the Phase II Study: Noninferiority Study of Doxorubicin with Upfront Dexrazoxane plus Olaratumab for Advanced or Metastatic Soft-Tissue Sarcoma.
    Van Tine BA; Hirbe AC; Oppelt P; Frith AE; Rathore R; Mitchell JD; Wan F; Berry S; Landeau M; Heberton GA; Gorcsan J; Huntjens PR; Soyama Y; Vader JM; Alvarez-Cardona JA; Zhang KW; Lenihan DJ; Krone RJ
    Clin Cancer Res; 2021 Jul; 27(14):3854-3860. PubMed ID: 33766818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardioprotective effect of dexrazoxane in patients with breast cancer treated with anthracyclines in adjuvant setting: a 10-year single institution experience.
    Testore F; Milanese S; Ceste M; de Conciliis E; Parello G; Lanfranco C; Manfredi R; Ferrero G; Simoni C; Miglietta L; Ferro S; Giaretto L; Bosso G
    Am J Cardiovasc Drugs; 2008; 8(4):257-63. PubMed ID: 18690759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dexrazoxane Significantly Reduces Anthracycline-induced Cardiotoxicity in Pediatric Solid Tumor Patients: A Systematic Review.
    Liesse K; Harris J; Chan M; Schmidt ML; Chiu B
    J Pediatr Hematol Oncol; 2018 Aug; 40(6):417-425. PubMed ID: 29432315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemotherapy-induced cardiotoxicity in children.
    Bansal N; Amdani S; Lipshultz ER; Lipshultz SE
    Expert Opin Drug Metab Toxicol; 2017 Aug; 13(8):817-832. PubMed ID: 28679288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exposure to anthracyclines during childhood causes cardiac injury.
    Lipshultz SE
    Semin Oncol; 2006 Jun; 33(3 Suppl 8):S8-14. PubMed ID: 16781284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
    Seymour L; Bramwell V; Moran LA
    Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of cardiotoxicity of anthracycline-containing chemotherapy regimens in patients with bone and soft tissue sarcomas: A study of the FDA adverse event reporting system joint single-center real-world experience.
    Mo Z; Deng Y; Bao Y; Liu J; Jiang Y
    Cancer Med; 2023 Dec; 12(24):21709-21724. PubMed ID: 38054208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term serial echocardiographic examination of late anthracycline cardiotoxicity and its prevention by dexrazoxane in paediatric patients.
    Elbl L; Hrstkova H; Tomaskova I; Blazek B; Michalek J
    Eur J Pediatr; 2005 Nov; 164(11):678-84. PubMed ID: 16044276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective Evaluation of Doxorubicin Cardiotoxicity in Patients with Advanced Soft-tissue Sarcoma Treated in the ANNOUNCE Phase III Randomized Trial.
    Jones RL; Wagner AJ; Kawai A; Tamura K; Shahir A; Van Tine BA; Martín-Broto J; Peterson PM; Wright J; Tap WD
    Clin Cancer Res; 2021 Jul; 27(14):3861-3866. PubMed ID: 33632930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Dexrazoxane in patients with B-lymphomas or acute leukemias in the 2nd complete remission enables further therapy with cardiotoxic anthracyclines over recommended cumulative doses].
    Lemez P; Stejskal J; Cahová S; Holub M; Svítil P; Maresová J; Vásová I; Boudová L; Benesová V; Dvoráková D; Fisar J; Slavícek L
    Vnitr Lek; 2004 Jun; 50(6):438-46. PubMed ID: 15346637
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dexrazoxane : a review of its use for cardioprotection during anthracycline chemotherapy.
    Cvetković RS; Scott LJ
    Drugs; 2005; 65(7):1005-24. PubMed ID: 15892593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk Factor Analysis for Secondary Malignancy in Dexrazoxane-Treated Pediatric Cancer Patients.
    Kim H; Kang HJ; Park KD; Koh KN; Im HJ; Seo JJ; Lee JW; Chung NG; Cho B; Kim HK; Lee JM; Hah JO; Lee JA; Lee YH; Park SK; Baek HJ; Kook H; Kim JY; Kim HS; Kim HM; Chueh HW; Park M; Yoon HS; Lee MJ; Choi HS; Ahn HS; Kawano Y; Park JW; Hahn S; Shin HY
    Cancer Res Treat; 2019 Jan; 51(1):357-367. PubMed ID: 29764117
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Humanin analog enhances the protective effect of dexrazoxane against doxorubicin-induced cardiotoxicity.
    Lue Y; Gao C; Swerdloff R; Hoang J; Avetisyan R; Jia Y; Rao M; Ren S; Atienza V; Yu J; Zhang Y; Chen M; Song Y; Wang Y; Wang C
    Am J Physiol Heart Circ Physiol; 2018 Sep; 315(3):H634-H643. PubMed ID: 29775411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk-benefit of dexrazoxane for preventing anthracycline-related cardiotoxicity: re-evaluating the European labeling.
    Reichardt P; Tabone MD; Mora J; Morland B; Jones RL
    Future Oncol; 2018 Oct; 14(25):2663-2676. PubMed ID: 29747541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of dexrazoxane for clinical and subclinical cardiotoxicity in children with acute myeloid leukemia.
    Sánchez-Medina J; Gonzalez-Ramella O; Gallegos-Castorena S
    J Pediatr Hematol Oncol; 2010 May; 32(4):294-7. PubMed ID: 20404753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dexrazoxane. A review of its use as a cardioprotective agent in patients receiving anthracycline-based chemotherapy.
    Wiseman LR; Spencer CM
    Drugs; 1998 Sep; 56(3):385-403. PubMed ID: 9777314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiac complications in childhood cancer survivors treated with anthracyclines.
    Franco VI; Lipshultz SE
    Cardiol Young; 2015 Aug; 25 Suppl 2():107-16. PubMed ID: 26377717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anthracycline induced cardiac toxicity in pediatric Ewing sarcoma: a longitudinal study.
    Brown TR; Vijarnsorn C; Potts J; Milner R; Sandor GG; Fryer C
    Pediatr Blood Cancer; 2013 May; 60(5):842-8. PubMed ID: 23382019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.